Andrew Menzies-Gow, ATS 2021: Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma

It was a pleasure to talk to Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College, London, UK) around his recent analysis of the NAVIGATOR data, investigating the effect of tezepelumab in OCS-dependent severe asthma patients (Clinical Trial Identifier: NCT03347279). The abstract ‘Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the […]

Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data

We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough. The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented […]

Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome

We were delighted to catch up with Dr Sara Tomassetti (Careggi University Hospital, Florence, Italy) around interstitial lung changes following SARS-CoV-2 infection. The abstract ‘A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COVID-19 Interstitial Lung Syndrome PCOILS.‘ (ABSTRACT NUMBER: A1748) was presented at ATS 2021 International Conference, 14-19 May, 2021. Questions What […]

Andrew Bush, IPCRG 2021: Persistent Bacterial Bronchitis & Bronchiectasis in Children

We were delighted to speak with Professor Andrew Bush (Imperial Centre for Paediatrics and Child Health, London, UK) around his presentation on ‘Persistent Bacterial Bronchitis & Bronchiectasis in Children‘, which was presented at The IPCRG 10th World Conference, 6-8 May, 2021. Questions Could you give us a brief overview of persistent bacterial bronchitis (PBB) and […]

Dupilumab—A Potential New Biologic for Chronic Rhinosinusitis with Nasal Polyps

US Respiratory & Pulmonary Diseases. 2020;5(1):15-7 DOI: https://doi.org/10.17925/USPRD.2020.5.1.15

Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]

Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease

US Respiratory and Pulmonary Diseases. 2020;5(1):28-32 DOI: https://doi.org/10.17925/USPRD.2020.5.1.28

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis of the skin and other organs. It has a range of clinical manifestations, and the typical internal organs involved include the lungs, kidneys, heart, and gastrointestinal tract. Though it is an uncommon condition, the mortality rate of this disease is higher than any […]

Evidence and E-cigarettes – The English Perspective

European Respiratory & Pulmonary Diseases. 2019;5(1):10–11

Recently, there has been much media coverage on the topic of e-cigarettes. Approaches to new data suggesting that e-cigarettes may be harmful have differed between countries. In particular, the attitude of public health bodies in England has differed significantly from those in other countries internationally. American electronic cigarette company Juul has been accused of deliberately […]

Elexacaftor-tezacaftor-ivacaftor—A Combination Therapy for Phe508del Cystic Fibrosis

US Respiratory & Pulmonary Diseases. 2019;4(1):15–9

Cystic fibrosis (CF), an inherited disease affecting all races and ethnicities, results from defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which leads to dysregulations in the ion and fluid balance across epithelial membranes throughout the body.1–3 The CFTR protein is an anion channel that functions as a transmembrane traffic ATPase which is […]